This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Innophos (IPHS) Earnings Lag Estimates in Q3, Revenues Beat
by Zacks Equity Research
Softer demand, discontinuation of the low-margin nutrition trading business and the indirect effects of tariffs affected Innophos (IPHS) in Q3.
Innophos (IPHS) Earnings Top Estimates in Q2, Revenues Lag
by Zacks Equity Research
Weaker demand, discontinuation of low-margin nutrition trading business and effects of tariffs hurt Innophos' (IPHS) Q2 sales.
Innophos Holdings (IPHS) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Innophos (IPHS) delivered earnings and revenue surprises of 22.86% and -7.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Innophos Holdings (IPHS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Innophos (IPHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Innophos Holdings (IPHS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Innophos (IPHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Innophos Holdings (IPHS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Innophos (IPHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Innophos (IPHS) Earnings Top Estimates in Q4, Sales Flat Y/Y
by Anindya Barman
Innophos (IPHS) gains from a stabilized base business and pricing actions in Q4. It envisions revenues in 2019 to be mostly in line with the 2018 level.
Innophos (IPHS) Earnings Miss Estimates in Q3, Sales Rise Y/Y
by Zacks Equity Research
Innophos (IPHS) expects year-over-year adjusted EPS growth of 3-7% in 2018.
What Could Dampen Chemical Industry Momentum?
by Zacks Equity Research
There are a few reasons to be mindful about the chemical industry in the near term.
Innophos (IPHS) Q4 Earnings Lag Estimates, Sales Up Y/Y
by Zacks Equity Research
Strength in the FHN segment drove Innophos Holdings' (IPHS) revenues in Q4, but the company's earnings missed expectations.
Innophos Holdings (IPHS) Stock Up 15% in 3 Months: Here's Why
by Zacks Equity Research
Strong Q2 results, healthy outlook and upbeat prospects stemming from Novel Ingredients buyout have provided a boost to Innophos' (IPHS) shares.
Chemours' (CC) Solid Product Offerings Make it a Must Buy
by Zacks Equity Research
The Chemours Company (CC) is poised to gain from end-market demand for its products. Also, innovative products and expansionary efforts will prove advantageous.
PPG Industries' (PPG) Teslin Substrate Gets ISEGA Certificate
by Zacks Equity Research
PPG Industries' (PPG) Teslin Food-Grade substrate receives ISEGA certification, which can be safely used for numerous European packaging applications and food labeling.
Praxair Gains From Contract Wins, Solid Demand, Risks Remain
by Zacks Equity Research
Praxair (PX) will gain from diversified business structure, solid product demand and contract wins. High debt, stiff competition and global uncertainties remain issues.
Top Ranked Income Stocks to Buy for September 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 5th:
New Strong Buy Stocks for September 1st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
5 Reasons to Add Innophos (IPHS) Stock to Your Portfolio
by Zacks Equity Research
Based on its compelling prospects, we believe Innophos (IPHS) has plenty of upside potential.
New Strong Buy Stocks for August 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Innophos Declares Closure of Novel Ingredients Acquisition
by Zacks Equity Research
Innophos Holdings (IPHS) announced the closure of its acquisition deal with Novel Ingredients, creating a $0.5 billion Food, Health and Nutrition platform.
New Strong Buy Stocks for August 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Here's Why Innophos Holdings is a Good Investment Choice
by Zacks Equity Research
Innophos Holdings, Inc. (IPHS) is poised to gain from its cost-savings initiatives and Novel Ingredients buyout. The acquisition will help in creating a Food, Health and Nutrition platform.
New Strong Buy Stocks for August 11th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Chemical Stocks Earnings Roster for May 1: CC, CBT & IPHS
by Zacks Equity Research
We peek at three chemical companies that are slated to report quarterly results on May 1.
New Strong Sell Stocks for April 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zacks Industry Outlook Highlights: Kraton, Innophos Holdings, Trecora Resources and Rayonier Advanced Materials
by Zacks Equity Research
Zacks Industry Outlook Highlights: Kraton, Innophos Holdings, Trecora Resources and Rayonier Advanced Materials